Drug intelligence / Profile preview

ADC2313

Development stage: Preclinical
Lead developer: Hangzhou Adcoris Biopharmaceuticals
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ADC2313 is an antibody-drug conjugate (ADC) developed by Hangzhou Adcoris Biopharmacy. It is currently in the discovery phase and is being investigated for the treatment of neoplasms, specifically solid tumors. As an ADC, it combines a monoclonal antibody with a cytotoxic payload to selectively target and kill cancer cells while minimizing toxicity to normal tissues. The precise molecular target and payload for ADC2313 have not been disclosed publicly as of the latest update[1].

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)MET (Mesenchymal-epithelial transition factor receptor)

Beyond the preview

Go deeper on ADC2313.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADC2313.

Explore the full profile